In conclusion, the use of anti-VEGFR agents in advanced NSCLC did significantly increase the risk of hypertension and FAEs, but not for ATEs or VTEs, GI perforation, or hemorrhagic events. Here, KDR is linked to non-small cell lung carcinoma.